Theravance To Buy Back $250 Mln Of Shares

Theravance Biopharma, Inc. (TBPH), a company focused on serious lung diseases, said on Monday that it has started a $250 million capital return program.

With this move, Theravance has inked a deal to buy back its 9.6 million shares from GSK Plc (GSK), for $9.75 per share.

The share purchase is expected to be closed on September 20.

The drug maker said that it aims to start a Dutch auction tender offer to buy around $95 million of its shares in the near term.

Subsequent to the close of the tender offer, Theravance also intends to repurchase around $60 million of its shares by 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton. Elon Musk, who recently took Twitter Inc. private in a $44-billion deal, accused Apple Inc. of threatening to block the social media platform from its app store without giving the reason. In a series of tweets on Monday, the Tesla founder and CEO also said the tech giant had stopped advertising on Twitter, and that it was pressuring the firm over content moderation demands.
Follow RTT